Yi ZM, et al. - Researchers sought to appraise the efficacy, safety, and cost-effectiveness of levodopa/carbidopa/entacapone (LCE) vs levodopa/dopa-decarboxyiase inhibitor (DDCI) for the treatment of Parkinson’s disease (PD). As per the findings, LCE improved patient Unified Parkinson’s Disease Rating Scale (UPDRS) II score, UPDRS III score and Schwab and England daily activity rating vs levodopa–DDCI. No statistically significant variation was reported in the risk of serious adverse events (AEs) or discontinuation due to AEs in patients with LCE, and the risk of total AEs was discovered to be higher in the LCE group. It was reasoned that LCE could improve PD patients’ motor symptoms and daily living functioning when compared with levodopa/DDCI.